GNLX Stock — Genelux Corporation: Cash, EV, Pipeline

Share price

$2.53

Market cap

$114.5M

Cash

$18.7M

Enterprise value

$95.8M

Balance sheet

Cash	$18.7M
Debt	$0.0M
Net cash	$18.7M
Enterprise value	$95.8M
Basic shares	45.1M shares
Fully diluted shares	57.2M shares
Fully diluted market cap	$144.8M
Cash per share	$0.41

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GNLX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	olvimulogene nanivacirepvec	Phase 3	Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer	2H 2026
Jan 12 - Feb 23	Olvi-Vec	Phase 2	SCLC, Extensive Stage	—
Mar 15 - Apr 26	Olvimulogene nanivacirepvec	Phase 2	Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Olvi-Vec

Phase 3 · Active Modality: oncolytic virus (modified vaccinia virus, VACV)

Aliases olvimulogene nanivacirepvec

Partnerships Newsoara: license agreement covering oncolytic viruses incl. Olvi-Vec (Newsoara funds/conducts VIRO-25 Phase 2 in NSCLC in US and China)

Indications

platinum-resistant/refractory ovarian cancer (Phase 3)
non-small cell lung cancer (NSCLC) (Phase 2)

Status note Lead product candidate; proprietary modified vaccinia virus oncolytic immunotherapy. Phase 3 On Prime/GOG-3076 registration trial ongoing; Phase 1b/2 VIRO-15 in PRROC (translational/clinical findings published June 2026). VIRO-25 Phase 2 in NSCLC run by Newsoara. Extensive engineered oncolytic VACV library (CHOICE platform) with no distinct additional candidate named.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	olvimulogene nanivacirepvec
Lead indication	Platinum-resistant Ovarian Cancer
Lead phase	Phase 3
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05281471	Phase 3	Recruiting	Sponsor	GNLX	—	Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer	2H 2026
NCT06463665	Phase 2	Recruiting	Sponsor	GNLX	—	Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer	—
NCT07136285	Phase 2	Recruiting	Collaborator	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.	—	SCLC, Extensive Stage	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Genelux Corporation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GNLX — Genelux Corporation